Medtronic Appoints Paolo Di Vincenzo as President of Neuromodulation Business

Oct 06, 2023 00:01 CST Updated 00:01

Medtronic

Medical Device Manufacturer

Source: Medtronic Official Website, Siyu

Reprint Requirements: Please indicate the source of the article at the beginning of the text, and it can be reprinted directly.

On October 4, 2023, Medtronic (NYSE: MDT), a global leader in healthcare technology, announced,Paolo Di Vincenzo will join the company on October 30 as President of the Neuromodulation Business.In this position, Di Vincenzo will be responsible for the overall strategic direction and daily operations of Medtronic's neuromodulation business.

Medtronic's fiscal year is already halfway through, and the companyFinally FilledNeuromodulationDepartment Vacancy。According to reports,Di VincenzoWill replace the departmentFormer PresidentNnamdi Njoku，The latter left Medtronic in March to joinZimmer Biomet, serving as the President of Sports Medicine, Surgery, Upper Limb, and Restorative Therapy.

It is reported that Di VincenzoHe worked at Smith+Nephew for nearly 10 years, serving as Senior Vice President and General Manager of Advanced Wound Management in the U.S.During the period of employment with the company,Di VincenzoAlso holds global marketing and leadership positions.Upon joiningSmith & NephewPreviously, Di Vincenzo held various marketing leadership roles at wound care company Systagenix (then Acely), BD Medical, and Roche Diagnostics, with increasing responsibilities.

▲Paolo Di Vincenzo

Executive Vice President of Medtronic and President of the Neuroscience PortfolioBrett WallIndicates: "Paolo Di VincenzoIs a results-oriented, people-centric leader."I am very glad that he can join this team, asNeuromodulation TechnologyEntering the Era of Personalized Medicine.He willEnhanceMedtronicPlay a key role in these areas of capability, while drivingBusiness Execution, ThisIn line with Medtronic's focus on a performance-driven culture.”

Notably, Medtronic's neuromodulation business appointed Dr. Ashwini (Ash) Sharan as the company’s Chief Medical Officer just this past June. This marks another significant personnel appointment in the department within four months.Review:Medtronic Announces Another Round of Personnel Changes）

#Learn about Medtronic's neuromodulation business

The neuromodulation business is part of Medtronic's neuroscience portfolio,Spinal Cord Stimulation BusinessAndBrain Modulation BusinessComposed of innovative therapies and technologies designed to help patients relieve pain, restore function, and regain movement.InMedtronic's latest financial report for the first quarter of the 2024 fiscal year shows that,Neuromodulation business grew by 3.7%. The division's total global revenue for the quarter was $420 million.。

Among them, the brain modulation business,AdoptBrainSense™ Technology's Percept™ PC Deep Brain (DBS) Neurostimulator Shows Strong Performance.Percepept™PC isThe FirstWith complete sensing, directionality, and visual programming capabilitiesDBS System，Used to treat Parkinson's disease, dystonia, tremor, and epilepsy. Facing the intricate brain networks, the Percept™ PC neurostimulator, equipped with BrainSense™ sensing technology, is a research achievement developed over more than a decade by Medtronic’s R&D department. While delivering electrical stimulation therapy to the patient's brain, it senses specific brain signals related to disease symptoms and analyzes them using intelligent algorithms, providing doctors with objective data for treatment strategies, thereby offering personalized and precise treatment to patients.

And the field of spinal cord stimulation`, Company`The increasing trials and implantation rates of the differentiated corporate DTM™ programming mode on the Intellis™ platform have raised the bar for spinal cord stimulation.Performance。DTM™ ProgramThe control mode is based on the different gene expression of cells in pain and normal states. Within a stimulation cycle, it uses a personalized multiplexing algorithm to provide stimulation parameters that combine low and high energy to different contacts of electrodes placed in different spinal segments (with varying degrees of glial cell aggregation), aiming to maximally restore cells from the pain state to the normal state through this programming process.

Intellis™, as the world's smallest neurostimulator currently available for spinal cord stimulation therapy, features several revolutionary technological designs:

Innovative Battery Technology Overdrive™: Battery capacity remains over 95% after 9 years of use, unaffected by treatment stimulation parameter settings or patient charging habits; full charge from empty takes only 1 hour.
Position Adjustment Technology AdaptiveStim™: Allows for setting up to 7 personalized parameter schemes for different patient positions, ensuring suitable stimulation parameters for virtually any body state, enhancing patient comfort;
MRI Scanning Technology SureScan™: Compatible with 1.5T MRI-safe scans for all body parts without restriction.

In addition, in the spinal cord stimulation pipeline, AugustMedtronic has just announced that its Inceptiv™ Closed-Loop Rechargeable Spinal Cord Stimulator (SCS) has received CE certification.This is Medtronic's first SCS device to offer closed-loop functionality., which can perceive each person's unique biological signals and adjust the stimulation as needed at any time, keeping the treatment in sync with daily life movements.

Editor-in-Chief | Zhao Qing Reviewed by | Yi He Typeset by | Miya